6h
Hexcel Corporation: Priced For Perfection Despite Operational Bottlenecks And Valuation Disconnect
Hexcel is rated Sell due to delivery bottlenecks and rigid costs, and a DCF fair value of $41 vs. $84.95 implies a 52% ...
By Tatiana Bautzer and Prakhar Srivastava Oct 13 (Reuters) - Citigroup beat Wall Street estimates for third-quarter profit on ...
September found Romania in the same state of limbo that marked the end of summer: a dismissed government forced to handle ...
9h
Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?
Merck & Co., Inc. (NYSE:MRK) closed at $145.45 on October 12. The stock has returned 21% during the last six months, compared ...
By Utkarsh Shetti and Nivedita Balu Oct 13 (Reuters) - Wells Fargo beat Wall Street estimates for third-quarter profit on ...
Takeda is rated a buy, reflecting recent drug approval, a robust future pipeline, global reach & an investment-grade rating.
Three jobs left you with three 401(k)s that have never met each other, and the hidden cost of keeping them apart goes well ...
The CGT shift is pushing investors towards income. Here’s where WAM's Damien Boey and Solaris' Charles Casey are looking.
BPcontinues to make progress cutting net debt. Consensus expectation are likely to move higher after its business update ...
BIO-key International Inc. stocks have been trading up by 139.39 percent amid bullish sentiment surrounding its biometric ...
Cabaletta Bio Inc. stocks have been trading down by -10.34 percent amid negative sentiment over its latest clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results